Hepatitis C Virus Infection and Rheumatic Diseases: the Impact of Direct-Acting Antiviral Agents

Cacoub, P.; Commarmond, C.é; Sadoun, D.; Desbois, A.C.

Rheumatic Diseases Clinics of North America 43(1): 123-132

2017


ISSN/ISBN: 1558-3163
PMID: 27890169
DOI: 10.1016/j.rdc.2016.09.011
Accession: 057981245

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Chronic hepatitis C virus (HCV) infection is associated with liver and extrahepatic complications, including B-cell lymphoma, cardiovascular and kidney diseases, glucose metabolism impairment and rheumatic conditions ie, arthralgia, myalgia, cryoglobulinemia vasculitis, sicca syndrome and the production of autoantibodies. The treatment has long been based on interferon alpha (IFN) that was found poorly effective, and contraindicated in many autoimmune/inflammatory disorders because of possible exacerbation of rheumatic disorders. The recent emergence of new oral IFN-free combinations offers an opportunity for HCV infected patients with autoimmune/inflammatory disorders to be cured with a short treatment duration and low risk of side effects.